Sun Pharmaceutical Industries dividend and valuation
Valuation
Sun Pharmaceutical Industries paid ₹16.00 per share in dividends over the last 12 months (yield 0.9%). Last ex-dividend date: July 7, 2026. The P/E ratio is 40.9. The average price target of 33 analysts is ₹2,111.94.
Data as of November 17, 2026
Sun Pharmaceutical Industries compared with similar companies
Sun Pharmaceutical Industries's P/E (trailing 12 months): 40.9, in line with the median of a group of 11 similar companies (40.9).
| Metric | Sun Pharmaceutical Industries | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 40.9 | 40.9 | 28.2 – 83.4 | Middle |
| Forward P/E | 29.7 | 29.7 | 24.6 – 45.7 | Middle |
| EV/EBITDA | 24.4 | 26.9 | 17.8 – 43.4 | Middle |
| Price/book | 5.01 | 4.74 | 3.41 – 11.4 | Middle |
| Price/sales | 7.27 | 9.71 | 4.11 – 14.7 | Middle |
| Gross margin | 79.3% | 75.9% | 64.1% – 84.0% | Middle |
| Operating margin | 23.3% | 24.1% | 19.7% – 32.8% | Middle |
| Net margin | 17.8% | 17.8% | 13.0% – 32.2% | Middle |
| ROE | 13.1% | 15.2% | 13.5% – 19.8% | Low |
| Debt/equity | 0.04 | 0.11 | 0.02 – 0.44 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Sun Pharmaceutical Industries: valuation over time
On the latest fiscal year's earnings (2026), Sun Pharmaceutical Industries's P/E today is 39.3, in line with the median of its last 10 fiscal years (39.3; between 22.5 and 67.3 from 2017 to 2026). Relative to earnings, it costs about the same as in the past. The dividend yield (0.9%) is in line with the median of the last 10 fiscal years (0.9%).
| Fiscal year | Price at year end | Earnings per share | P/E | Dividend per share | Yield |
|---|---|---|---|---|---|
| Mar 2026 | ₹1,757.20 | ₹47.80 | 36.8 | ₹16.00 | 0.9% |
| Mar 2025 | ₹1,734.70 | ₹45.55 | 38.1 | ₹16.00 | 0.9% |
| Mar 2024 | ₹1,620.55 | ₹39.90 | 40.6 | ₹13.50 | 0.8% |
| Mar 2023 | ₹983.10 | ₹35.30 | 27.8 | ₹11.50 | 1.2% |
| Mar 2022 | ₹914.75 | ₹13.60 | 67.3 | ₹10.00 | 1.1% |
| Mar 2021 | ₹597.80 | ₹12.10 | 49.4 | ₹7.50 | 1.3% |
| Mar 2020 | ₹352.30 | ₹15.69 | 22.5 | ₹4.00 | 1.1% |
| Mar 2019 | ₹475.45 | ₹11.10 | 42.8 | ₹2.75 | 0.6% |
| Mar 2018 | ₹495.10 | ₹8.70 | 56.9 | ₹2.00 | 0.4% |
| Mar 2017 | ₹688.15 | ₹28.98 | 23.7 | ₹3.50 | 0.5% |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only); yield = dividend per share for the year divided by the same price. Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above; today's yield uses dividends over the last 12 months.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- ₹4.48T
- Enterprise value
- ₹4.17T
- PEG
- 1.04
- EV/revenue
- 6.77
Profitability and growth
- ROA
- 8.2%
- ROIC
- 18.4%
- Revenue growth (year over year)
- 11.9%
- Earnings growth (year over year)
- -36.2%
Financial health
- Total cash
- ₹335.7B
- Total debt
- ₹32.41B
- Current ratio
- 2.94
- Quick ratio
- 2.18
- Piotroski F-Score
- 5.00
Dividends
- Annual dividend per share
- ₹16.00
- Dividend yield
- 0.9%
- Payout ratio
- 35.0%
- Ex-dividend date
- July 7, 2026
Analysts and estimates
- Average price target
- ₹2,111.94
- Median price target
- ₹2,140.00
- High price target
- ₹2,320.00
- Low price target
- ₹1,770.00
- Analysts with a price target
- 33
- Consensus
- Buy
- Forward EPS
- ₹62.79
- EPS estimate, current year
- ₹53.50
Shares and trading
- Beta
- 0.13
- Average volume
- 1.8M
- Shares outstanding
- 2.4B
- Float
- 830.49M
- Institutional ownership
- 29.5%
- Insider ownership
- 55.6%
